Cell therapy · Kills target cells · developed by In8bio
Allogeneic gene-modified gamma delta T-cells are genetically modified donor-derived T-lymphocytes that kill tumor cells directly without MHC-mediated antigen presentation, secrete interferon-gamma, and activate cytotoxic T-lymphocyte responses. They are studied in glioblastoma in combination with temozolomide, to which the genetic modification may confer resistance.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05664243 | Phase 1/2 | Glioblastoma | Active not recruiting | INAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glioblastoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the INAB page.
See INAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INAB catalysts and pipeline →